Wahl Bryan 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 19, 2026
Research Summary
AI-generated summary of this filing
Tarsus (TARS) General Counsel Bryan Wahl Sells 12,440 Shares
What Happened
Bryan Wahl, General Counsel of Tarsus Pharmaceuticals (TARS), reported three open-market sales totaling 12,440 shares between 2026-03-17 and 2026-03-19. The sales were: 4,084 shares @ $69.42 on 2026-03-17 ($283,511), 4,125 shares @ $68.71 on 2026-03-18 ($283,429), and 4,231 shares @ $67.00 on 2026-03-19 ($283,477). Total gross proceeds were approximately $850,417. These were disposals (S) and not purchases — routine sell-to-cover transactions rather than a market-timing buy signal.
Key Details
- Transaction dates and prices:
- 2026-03-17: 4,084 shares @ $69.42 = $283,511
- 2026-03-18: 4,125 shares @ $68.71 = $283,429
- 2026-03-19: 4,231 shares @ $67.00 = $283,477
- Total: 12,440 shares sold for ~$850,417.
- Shares owned after transaction: not specified in the filing.
- Footnote (F1): Sales were mandated sell-to-cover to satisfy tax withholding on vested Restricted Stock Units (RSUs); not discretionary trades by the reporting person.
- Transaction code: S = Sale. Filing date: 2026-03-19 — transactions reported timely (within Form 4 reporting window).
Context
Sell-to-cover transactions are common when RSUs vest and the employer requires withholding by selling a portion of shares; they generally do not indicate the insider's view of the company's prospects. For retail investors, purchases generally carry more informational weight than mandated sales like these.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-03-17$69.42/sh−4,084$283,511→ 72,315 total - Sale
Common Stock
[F1]2026-03-18$68.71/sh−4,125$283,429→ 68,190 total - Sale
Common Stock
[F1]2026-03-19$67.00/sh−4,231$283,477→ 63,959 total
Footnotes (1)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.